Trending: Bristol Myers Squibb Buying Mirati Therapeutics
October 09 2023 - 10:30AM
Dow Jones News
10:00 ET -- Bristol Myers Squibb is one of the most mentioned
companies in the U.S. across all news items in the last 12 hours,
according to Factiva data. Bristol Myers Squibb is buying Mirati
Therapeutics in a deal that values the oncology developer at up to
$5.8 billion. The biopharmaceutical company on Sunday said that it
had entered into a definitive merger agreement with Mirati under
which it would pay $58.00 a share in cash. Mirati stockholders will
also receive one non-tradable contingent value right per share,
potentially worth $12.00 a share in cash. Dow Jones & Co. owns
Factiva. (chris.wack@wsj.com)
(END) Dow Jones Newswires
October 09, 2023 10:15 ET (14:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Mirati Therapeutics (NASDAQ:MRTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Mirati Therapeutics (NASDAQ:MRTX)
Historical Stock Chart
From Oct 2023 to Oct 2024